The urgent need to develop new drugs and tools for the treatment of Chagas disease

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 1, 2011, Pages 5-7

  Muñoz, Maria J ^a   Murcia, Laura ^a   Segovia, Manuel ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

Author keywords

Chagas disease; drug development; prognosis markers; treatment follow up; Trypanosoma cruzi

Indexed keywords

2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; ALBACONAZOLE; ALLOPURINOL; AMIODARONE; ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT; BENZNIDAZOLE; CRUZIPAIN; CRUZIPAIN 5; DB 766; E 5700; ER 119884; FLUCONAZOLE; ITRACONAZOLE; K 777; KETOCONAZOLE; LANOSTEROL SYNTHASE; NIFURTIMOX; POSACONAZOLE; RAVUCONAZOLE; SQUALENE SYNTHASE; STEROL 14ALPHA DEMETHYLASE; UNCLASSIFIED DRUG;

ACUTE DISEASE; BONE MARROW DEPRESSION; CHAGAS DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; DERMATITIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEMAGGLUTINATION TEST; HUMAN; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; NEUROLOGIC DISEASE; NONHUMAN; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; DRUG DESIGN; ERGOSTEROL; HUMANS; NITROFURANS; PROGNOSIS; TREATMENT OUTCOME; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 78650646790     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.144     Document Type: Review

References (23)

1. Clayton J. Chagas disease 101. Nature 465, S4-S5 (2010).
2. Clayton J. The promise of T. cruzi genomics. Nature 465, S16-S17 (2010).
3. Oliveira I, Torrico F, Muñoz J, Gascon J. Congenital transmission of Chagas disease: a clinical approach. Expert Rev. Anti Infect. Ther. 8(8), 945-956 (2010).
4. Alarcón de Noya B, Díaz-Bello Z, Colmenares C, et al. Large urban outbreak of orally acquired acute Chagas disease at a school in Caracas, Venezuela. J. Infect. Dis. 201, 1308-1315 (2010).
5. Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 115, 22-27 (2010).
6. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect. Dis. 1, 92-100 (2001).
7. Gascón J, Albajar P, Cañas E, et al. Diagnosis, management and treatment of chronic Chagas heart disease in areas where Trypanosoma cruzi infection is not endemic. Rev. Esp. Cardiol. 60, 285-293 (2007).
8. Rezende J. Diagnóstico de las manifestaciones digestivas de la enfermedad de Chagas. Enfermedades Emergentes 9, 22-27 (2007).
9. Murcia L, Carrilero B, Muñoz MJ, Iborra MA, Segovia M. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas disease: a prospective study in a non-disease-endemic country. J. Antimicrob. Chemother. 65, 1759-1764 (2010).
10. Solari A, Ortíz S, Soto A, et al. Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR. J. Antimicrob. Chemother. 48, 515-519 (2001).
11. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas disease: a systematic review with a meta-analysis. J. Antimicrob. Chemother. 64(6), 1139-1147 (2009).
12. Marin-Neto JA, Rassi A Jr, Avezum A Jr, et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem. Inst. Oswaldo Cruz. 104(1), 319-324 (2009).
13. Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas disease (American trypanosomiasis). Hum. Exp. Toxicol. 25(8), 471-479 (2006).
14. World Health Organization. Control of Chagas disease. Second Report of the WHO Expert Committee. WHO Technical Reports Series. WHO, Geneva, Switzerland, 905, 1-109 (2002).
15. Cancado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo 44, 29-37 (2002).
16. Galvão LMC, Nunes RMB, Canado JR, Brener Z, Krettli AU. Lytic antibodies titre as means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans. R. Soc. Trop. Med. Hyg. 87, 220-223 (1993).
17. Meira WS, Galvão LM, Gontijo ED, Machado-Coelho GL, Norris KA, Chiari E. Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients. J. Clin. Microbiol. 42(2), 707-712 (2004).
18. Flechas ID, Cuellar A, Cucunubá ZM, et al. Characterising the KMP-11 and HSP-70 recombinant antigens humoral immune response profile in chagasic patients. BMC Infect. Dis. 9, 186 (2009).
19. Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo Cruz. 104(1), 311-318 (2009).
20. Gerpe A, Odreman-Nunez I, Draper P, et al. Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action. Bioorg. Med. Chem. 16, 569-577 (2008).
21. Barr SC, Warner KL, Kornreic BG, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob. Agents Chemother. 49(12), 5160-5161 (2005).
22. Batista Dda G, Batista MM, de Oliveira GM, et al. Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas disease treatment. Antimicrob. Agents Chemother. 54(7), 2940-2952 (2010).
23. Rodrigues J. Present situation and new strategies for Chagas disease chemotherapy - a proposal. Mem. Inst. Oswaldo Cruz. 104(4), 549-554 (2009).